Leuvectin Followed By Surgery in Treating Patients With Stage II or Stage III Prostate Cancer
Leuvectin Followed By Surgery in Treating Patients With Stage II or Stage III Prostate Cancer
Bio2RDF identifier
NCT00004050
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00004050
identifiers.org URI
actual enrollment [clinicaltrials_vocabulary:actual-enrollment]
arm group [clinicaltrials_vocabulary:arm-group]
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
RATIONALE: Inserting th ...... or stage III prostate cancer.
brief title [clinicaltrials_vocabulary:brief-title]
Leuvectin Followed By Surgery ...... I or Stage III Prostate Cancer
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
collaborator [clinicaltrials_vocabulary:collaborator]
completion date [clinicaltrials_vocabulary:completion-date]
2003-04-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
OBJECTIVES:
- ...... were accrued for this study.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
1999-12-10T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]
is section 801 [clinicaltrials_vocabulary:is-section-801]
keyword [clinicaltrials_vocabulary:keyword]
stage IIA prostate cancer
stage IIB prostate cancer
stage III prostate cancer
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2014-07-25T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
link [clinicaltrials_vocabulary:link]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00004050
number of arms [clinicaltrials_vocabulary:number-of-arms]
official title [clinicaltrials_vocabulary:official-title]
Phase II Study Evaluating the ...... e Treatment of Prostate Cancer
org study id [clinicaltrials_vocabulary:org-study-id]
VCL-1102-202
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
primary completion date [clinicaltrials_vocabulary:primary-completion-date]
2003-04-01T00:00:00Z
responsible party [clinicaltrials_vocabulary:responsible-party]
secondary id [clinicaltrials_vocabulary:secondary-id]
UCLA-9901077-03B
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
1999-06-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2014-07-01T00:00:00Z
why stopped [clinicaltrials_vocabulary:why-stopped]
Development in prostate cancer indication halted
identifier
clinicaltrials:NCT00004050
title
Leuvectin Followed By Surgery ...... I or Stage III Prostate Cancer
@en